1	5	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Conclusions	_	_	NNS	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	Perspectives	_	_	NNS	_	_	_	_	_


1	EGFR-TKIs	_	_	NNS	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	currently	_	_	RB	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	standard	_	_	JJ	_	_	_	_	_
6	first-line	_	_	JJ	_	_	_	_	_
7	treatment	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	advanced	_	_	VBN	_	_	_	_	_
12	NSCLC	_	_	NN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	activating	_	_	VBG	_	_	_	_	_
15	EGFR	_	_	NN	_	_	_	_	_
16	mutations	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	targeted	_	_	VBN	_	_	_	_	_
3	therapies	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	usually	_	_	RB	_	_	_	_	_
6	well	_	_	RB	_	_	_	_	_
7	tolerated	_	_	VBN	_	_	_	_	_
8	comparative	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	conventional	_	_	JJ	_	_	_	_	_
11	chemotherapy	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	self-oral	_	_	JJ	_	_	_	_	_
3	administration	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	drug	_	_	NN	_	_	_	_	_
7	positively	_	_	RB	_	_	_	_	_
8	contributes	_	_	VBZ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	improving	_	_	VBG	_	_	_	_	_
11	patient	_	_	NN	_	_	_	_	_
12	compliance	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	reducing	_	_	VBG	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	use	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	hospital	_	_	NN	_	_	_	_	_
19	resources	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	this	_	_	DT	_	_	_	_	_
4	non-invasive	_	_	JJ	_	_	_	_	_
5	route	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	administration	_	_	NN	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	also	_	_	RB	_	_	_	_	_
10	associated	_	_	VBN	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	unpredictable	_	_	JJ	_	_	_	_	_
13	bioavailability	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	increased	_	_	VBN	_	_	_	_	_
16	risk	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	drug	_	_	NN	_	_	_	_	_
19	interactions	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	concerns	_	_	NNS	_	_	_	_	_
23	about	_	_	IN	_	_	_	_	_
24	patient	_	_	NN	_	_	_	_	_
25	safety	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	surveillance	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	follow-up	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Chronic	_	_	JJ	_	_	_	_	_
2	EGFR-TKIs	_	_	NNS	_	_	_	_	_
3	underdosage	_	_	NN	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	favor	_	_	VB	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	selection	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	resistant	_	_	JJ	_	_	_	_	_
10	clones	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	thus	_	_	RB	_	_	_	_	_
13	disease	_	_	NN	_	_	_	_	_
14	progression	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	overdosage	_	_	NN	_	_	_	_	_
18	may	_	_	MD	_	_	_	_	_
19	increase	_	_	VB	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	risk	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	dose-related	_	_	JJ	_	_	_	_	_
24	side	_	_	NN	_	_	_	_	_
25	effects	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Self-administration	_	_	NN	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	means	_	_	VBZ	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	severity	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	side	_	_	NN	_	_	_	_	_
9	effects	_	_	NNS	_	_	_	_	_
10	can	_	_	MD	_	_	_	_	_
11	be	_	_	VB	_	_	_	_	_
12	considerably	_	_	RB	_	_	_	_	_
13	impacted	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	patient	_	_	NN	_	_	_	_	_
16	behavior	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	e.	_	_	FW	_	_	_	_	_
19	g.	_	_	FW	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	dietary	_	_	JJ	_	_	_	_	_
22	habits	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	self-medicating	_	_	JJ	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	smoker	_	_	NN	_	_	_	_	_
27	status	_	_	NN	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	date	_	_	VB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	EGFR-TKIs	_	_	NNP	_	_	_	_	_
5	can	_	_	MD	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	administered	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	advanced	_	_	JJ	_	_	_	_	_
10	NSCLC	_	_	NNP	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	long	_	_	JJ	_	_	_	_	_
14	period	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	time	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	usually	_	_	RB	_	_	_	_	_
19	until	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	disease	_	_	NN	_	_	_	_	_
22	progresses	_	_	VBZ	_	_	_	_	_
23	or	_	_	CC	_	_	_	_	_
24	unacceptable	_	_	JJ	_	_	_	_	_
25	toxicity	_	_	NN	_	_	_	_	_
26	occurs	_	_	VBZ	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	early	_	_	JJ	_	_	_	_	_
3	intervention	_	_	NN	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	supportive	_	_	JJ	_	_	_	_	_
6	care	_	_	NN	_	_	_	_	_
7	strategies	_	_	NNS	_	_	_	_	_
8	can	_	_	MD	_	_	_	_	_
9	minimize	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	intensity	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	adverse	_	_	JJ	_	_	_	_	_
14	reactions	_	_	NNS	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	allow	_	_	VB	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	appropriate	_	_	JJ	_	_	_	_	_
19	dose	_	_	NN	_	_	_	_	_
20	adjustments	_	_	NNS	_	_	_	_	_
21	without	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	need	_	_	NN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	discontinue	_	_	VB	_	_	_	_	_
26	treatment	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	acute	_	_	JJ	_	_	_	_	_
29	toxicity	_	_	NN	_	_	_	_	_
30	follow-up	_	_	NN	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	side	_	_	NN	_	_	_	_	_
33	effect	_	_	NN	_	_	_	_	_
34	management	_	_	NN	_	_	_	_	_
35	is	_	_	VBZ	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	major	_	_	JJ	_	_	_	_	_
38	interest	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	medical	_	_	JJ	_	_	_	_	_
4	oncologists	_	_	NNS	_	_	_	_	_
5	should	_	_	MD	_	_	_	_	_
6	not	_	_	RB	_	_	_	_	_
7	only	_	_	RB	_	_	_	_	_
8	understand	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	AEs	_	_	NNP	_	_	_	_	_
11	associated	_	_	VBN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	these	_	_	DT	_	_	_	_	_
14	drugs	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	but	_	_	CC	_	_	_	_	_
17	also	_	_	RB	_	_	_	_	_
18	develop	_	_	VB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	necessary	_	_	JJ	_	_	_	_	_
21	skills	_	_	NNS	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	detect	_	_	VB	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	treat	_	_	VB	_	_	_	_	_
26	them	_	_	PRP	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	reduce	_	_	VB	_	_	_	_	_
29	morbidity	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	mortality	_	_	NN	_	_	_	_	_
32	as	_	_	RB	_	_	_	_	_
33	well	_	_	RB	_	_	_	_	_
34	as	_	_	IN	_	_	_	_	_
35	premature	_	_	JJ	_	_	_	_	_
36	discontinuation	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	treatment	_	_	NN	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Patient	_	_	NN	_	_	_	_	_
2	education	_	_	NN	_	_	_	_	_
3	on	_	_	IN	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	strategies	_	_	NNS	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	major	_	_	JJ	_	_	_	_	_
10	importance	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	can	_	_	MD	_	_	_	_	_
13	improve	_	_	VB	_	_	_	_	_
14	patient	_	_	NN	_	_	_	_	_
15	tolerance	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	quality	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	life	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	overall	_	_	JJ	_	_	_	_	_
23	treatment	_	_	NN	_	_	_	_	_
24	outcome	_	_	NN	_	_	_	_	_
25	by	_	_	IN	_	_	_	_	_
26	initiating	_	_	VBG	_	_	_	_	_
27	supportive	_	_	JJ	_	_	_	_	_
28	care	_	_	NN	_	_	_	_	_
29	soon	_	_	RB	_	_	_	_	_
30	after	_	_	IN	_	_	_	_	_
31	symptoms	_	_	NNS	_	_	_	_	_
32	occur	_	_	VBP	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Within	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	guidance	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	preventive	_	_	JJ	_	_	_	_	_
6	strategy	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	pharmacist	_	_	NN	_	_	_	_	_
10	can	_	_	MD	_	_	_	_	_
11	play	_	_	VB	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	major	_	_	JJ	_	_	_	_	_
14	role	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Good	_	_	JJ	_	_	_	_	_
2	knowledge	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	disease	_	_	NN	_	_	_	_	_
5	monitoring	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	response	_	_	NN	_	_	_	_	_
8	milestones	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	risks	_	_	NNS	_	_	_	_	_
13	versus	_	_	IN	_	_	_	_	_
14	benefits	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	treatment	_	_	NN	_	_	_	_	_
18	options	_	_	NNS	_	_	_	_	_
19	allows	_	_	VBZ	_	_	_	_	_
20	pharmacists	_	_	NNS	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	better	_	_	RBR	_	_	_	_	_
23	advise	_	_	VB	_	_	_	_	_
24	patients	_	_	NNS	_	_	_	_	_
25	or	_	_	CC	_	_	_	_	_
26	counsel	_	_	VB	_	_	_	_	_
27	patients	_	_	NNS	_	_	_	_	_
28	more	_	_	RBR	_	_	_	_	_
29	effectively	_	_	RB	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Nurses	_	_	NNS	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	prescribers	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	qualified	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	monitor	_	_	VB	_	_	_	_	_
8	toxicity	_	_	NN	_	_	_	_	_
9	risks	_	_	NNS	_	_	_	_	_
10	as	_	_	RB	_	_	_	_	_
11	closely	_	_	RB	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	possible	_	_	JJ	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Unfortunately	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	they	_	_	PRP	_	_	_	_	_
4	do	_	_	VBP	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	necessarily	_	_	RB	_	_	_	_	_
7	do	_	_	VB	_	_	_	_	_
8	so	_	_	RB	_	_	_	_	_
9	at	_	_	IN	_	_	_	_	_
10	regular	_	_	JJ	_	_	_	_	_
11	intervals	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Patients	_	_	NNS	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	connect	_	_	VB	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	pharmacists	_	_	NNS	_	_	_	_	_
6	who	_	_	WP	_	_	_	_	_
7	can	_	_	MD	_	_	_	_	_
8	provide	_	_	VB	_	_	_	_	_
9	them	_	_	PRP	_	_	_	_	_
10	additional	_	_	JJ	_	_	_	_	_
11	information	_	_	NN	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	complementary	_	_	JJ	_	_	_	_	_
14	recommendations	_	_	NNS	_	_	_	_	_
15	on	_	_	IN	_	_	_	_	_
16	AEs	_	_	NNP	_	_	_	_	_
17	without	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	need	_	_	NN	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	patients	_	_	NNS	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	rapidly	_	_	RB	_	_	_	_	_
24	contact	_	_	VB	_	_	_	_	_
25	prescribers	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	When	_	_	WRB	_	_	_	_	_
2	more	_	_	RBR	_	_	_	_	_
3	complex	_	_	JJ	_	_	_	_	_
4	or	_	_	CC	_	_	_	_	_
5	serious	_	_	JJ	_	_	_	_	_
6	AEs	_	_	NN	_	_	_	_	_
7	appear	_	_	VBP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	pharmacists	_	_	NNS	_	_	_	_	_
10	who	_	_	WP	_	_	_	_	_
11	work	_	_	VBP	_	_	_	_	_
12	closely	_	_	RB	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	nurses	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	prescribers	_	_	NNS	_	_	_	_	_
17	can	_	_	MD	_	_	_	_	_
18	propose	_	_	VB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	most	_	_	RBS	_	_	_	_	_
21	appropriate	_	_	JJ	_	_	_	_	_
22	therapeutic	_	_	JJ	_	_	_	_	_
23	strategies	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Finally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	medical	_	_	JJ	_	_	_	_	_
4	oncologists	_	_	NNS	_	_	_	_	_
5	able	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	understand	_	_	VB	_	_	_	_	_
8	AEs	_	_	NNP	_	_	_	_	_
9	along	_	_	IN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	patient	_	_	NN	_	_	_	_	_
12	education	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	collaboration	_	_	NN	_	_	_	_	_
15	between	_	_	IN	_	_	_	_	_
16	different	_	_	JJ	_	_	_	_	_
17	medical	_	_	JJ	_	_	_	_	_
18	professional	_	_	JJ	_	_	_	_	_
19	groups	_	_	NNS	_	_	_	_	_
20	for	_	_	IN	_	_	_	_	_
21	therapeutic	_	_	JJ	_	_	_	_	_
22	drug	_	_	NN	_	_	_	_	_
23	monitoring	_	_	NN	_	_	_	_	_
24	systems	_	_	NNS	_	_	_	_	_
25	are	_	_	VBP	_	_	_	_	_
26	needed	_	_	VBN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	but	_	_	CC	_	_	_	_	_
29	further	_	_	JJR	_	_	_	_	_
30	research	_	_	NN	_	_	_	_	_
31	on	_	_	IN	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	aforementioned	_	_	JJ	_	_	_	_	_
34	methods	_	_	NNS	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	relief	_	_	NN	_	_	_	_	_
37	for	_	_	IN	_	_	_	_	_
38	continued	_	_	VBN	_	_	_	_	_
39	TKI	_	_	NN	_	_	_	_	_
40	use	_	_	NN	_	_	_	_	_
41	should	_	_	MD	_	_	_	_	_
42	be	_	_	VB	_	_	_	_	_
43	also	_	_	RB	_	_	_	_	_
44	performed	_	_	VBN	_	_	_	_	_
45	in	_	_	IN	_	_	_	_	_
46	the	_	_	DT	_	_	_	_	_
47	future	_	_	NN	_	_	_	_	_
48	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	importance	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	proactive	_	_	JJ	_	_	_	_	_
5	patient	_	_	NN	_	_	_	_	_
6	follow-up	_	_	NN	_	_	_	_	_
7	must	_	_	MD	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	emphasized	_	_	VBN	_	_	_	_	_
10	rather	_	_	RB	_	_	_	_	_
11	than	_	_	IN	_	_	_	_	_
12	relying	_	_	VBG	_	_	_	_	_
13	on	_	_	IN	_	_	_	_	_
14	self-reporting	_	_	NN	_	_	_	_	_
15	between	_	_	IN	_	_	_	_	_
16	clinical	_	_	JJ	_	_	_	_	_
17	visits	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	randomized	_	_	JJ	_	_	_	_	_
3	trial	_	_	NN	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	receiving	_	_	VBG	_	_	_	_	_
8	chemotherapy	_	_	NN	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	advanced	_	_	JJ	_	_	_	_	_
11	cancer	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	web-based	_	_	JJ	_	_	_	_	_
14	symptom	_	_	NN	_	_	_	_	_
15	reporting	_	_	NN	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	automated	_	_	JJ	_	_	_	_	_
18	clinician	_	_	NN	_	_	_	_	_
19	e-mail	_	_	NN	_	_	_	_	_
20	alerts	_	_	NNS	_	_	_	_	_
21	resulted	_	_	VBN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	better	_	_	JJR	_	_	_	_	_
24	health-related	_	_	JJ	_	_	_	_	_
25	quality	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	life	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	fewer	_	_	JJR	_	_	_	_	_
30	emergency	_	_	NN	_	_	_	_	_
31	room	_	_	NN	_	_	_	_	_
32	visits	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	fewer	_	_	JJR	_	_	_	_	_
35	hospitalizations	_	_	NNS	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	superior	_	_	JJ	_	_	_	_	_
39	quality-adjusted	_	_	JJ	_	_	_	_	_
40	survival	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Cheema	_	_	NNP	_	_	_	_	_
4	et	_	_	FW	_	_	_	_	_
5	al.	_	_	FW	_	_	_	_	_
6	assessed	_	_	VBD	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	impact	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	interprofessional	_	_	JJ	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	proactive	_	_	JJ	_	_	_	_	_
14	follow-up	_	_	NN	_	_	_	_	_
15	algorithm	_	_	NN	_	_	_	_	_
16	on	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	incidence	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	dose	_	_	NN	_	_	_	_	_
21	interruptions	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	reductions	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	severity	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	AEs	_	_	NNP	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	patients	_	_	NNS	_	_	_	_	_
32	on	_	_	IN	_	_	_	_	_
33	afatinib	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	authors	_	_	NNS	_	_	_	_	_
3	reported	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	over	_	_	IN	_	_	_	_	_
6	half	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	first	_	_	JJ	_	_	_	_	_
9	AEs	_	_	NNP	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	one	_	_	CD	_	_	_	_	_
12	third	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	all	_	_	DT	_	_	_	_	_
15	grade	_	_	NN	_	_	_	_	_
16	1-2	_	_	CD	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	grade	_	_	NN	_	_	_	_	_
19	≥3	_	_	CD	_	_	_	_	_
20	AEs	_	_	NNS	_	_	_	_	_
21	were	_	_	VBD	_	_	_	_	_
22	detected	_	_	VBN	_	_	_	_	_
23	through	_	_	IN	_	_	_	_	_
24	proactive	_	_	JJ	_	_	_	_	_
25	follow-up	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	multi-disciplinary	_	_	JJ	_	_	_	_	_
3	AE	_	_	NN	_	_	_	_	_
4	algorithm	_	_	NN	_	_	_	_	_
5	resulted	_	_	VBD	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	low	_	_	JJ	_	_	_	_	_
9	rate	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	costly	_	_	JJ	_	_	_	_	_
12	emergency	_	_	NN	_	_	_	_	_
13	room	_	_	NN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	urgent	_	_	JJ	_	_	_	_	_
16	clinic	_	_	NN	_	_	_	_	_
17	visits	_	_	NNS	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	reduced	_	_	VBN	_	_	_	_	_
21	incidence	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	severe	_	_	JJ	_	_	_	_	_
24	drug-related	_	_	JJ	_	_	_	_	_
25	AEs	_	_	NN	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	discontinuation	_	_	NN	_	_	_	_	_
28	therapy	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	conclusion	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	when	_	_	WRB	_	_	_	_	_
5	closely	_	_	RB	_	_	_	_	_
6	monitoring	_	_	VBG	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	ability	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	clinicians	_	_	NNS	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	make	_	_	VB	_	_	_	_	_
15	rapid	_	_	JJ	_	_	_	_	_
16	therapeutic	_	_	JJ	_	_	_	_	_
17	decisions	_	_	NNS	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	event	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	medical	_	_	JJ	_	_	_	_	_
23	complications	_	_	NNS	_	_	_	_	_
24	is	_	_	VBZ	_	_	_	_	_
25	critical	_	_	JJ	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	diagnosis	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	management	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	TKI-related	_	_	JJ	_	_	_	_	_
33	side	_	_	NN	_	_	_	_	_
34	effects	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	even	_	_	RB	_	_	_	_	_
4	more	_	_	RBR	_	_	_	_	_
5	decisive	_	_	JJ	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	event	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	serious	_	_	JJ	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	even	_	_	RB	_	_	_	_	_
13	life-threatening	_	_	JJ	_	_	_	_	_
14	complications	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	good	_	_	JJ	_	_	_	_	_
4	clinician	_	_	NN	_	_	_	_	_
5	–	_	_	:	_	_	_	_	_
6	patient	_	_	NN	_	_	_	_	_
7	communication	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	drug	_	_	NN	_	_	_	_	_
10	patient	_	_	NN	_	_	_	_	_
11	education	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	early	_	_	JJ	_	_	_	_	_
14	detection	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	management	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	drug	_	_	NN	_	_	_	_	_
19	side	_	_	NN	_	_	_	_	_
20	effects	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	monitoring	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	disease	_	_	NN	_	_	_	_	_
26	response	_	_	NN	_	_	_	_	_
27	with	_	_	IN	_	_	_	_	_
28	plasma	_	_	NN	_	_	_	_	_
29	concentration	_	_	NN	_	_	_	_	_
30	quantification	_	_	NN	_	_	_	_	_
31	can	_	_	MD	_	_	_	_	_
32	also	_	_	RB	_	_	_	_	_
33	improve	_	_	VB	_	_	_	_	_
34	patient	_	_	NN	_	_	_	_	_
35	outcomes	_	_	NNS	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Close	_	_	JJ	_	_	_	_	_
2	cooperation	_	_	NN	_	_	_	_	_
3	between	_	_	IN	_	_	_	_	_
4	oncologists	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	internists	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	pharmaceutics	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	nurses	_	_	NNS	_	_	_	_	_
12	should	_	_	MD	_	_	_	_	_
13	become	_	_	VB	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	gold	_	_	NN	_	_	_	_	_
16	standard	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	comprehensive	_	_	JJ	_	_	_	_	_
20	clinical	_	_	JJ	_	_	_	_	_
21	care	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	advanced	_	_	JJ	_	_	_	_	_
24	NSCLC	_	_	NNP	_	_	_	_	_
25	patients	_	_	NNS	_	_	_	_	_
26	receiving	_	_	VBG	_	_	_	_	_
27	TKIs	_	_	NNPS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_

